<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vaginal intraepithelial neoplasia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vaginal intraepithelial neoplasia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Vaginal intraepithelial neoplasia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christine H Holschneider, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan S Berek, MD, MMS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Barbara Goff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alana Chakrabarti, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 22, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The diagnosis of vaginal intraepithelial neoplasia (VaIN) has increased steadily over the past several decades as a result of heightened awareness, expanded cytologic and human papillomavirus screening, and the liberal use of colposcopy. The relative rarity of VaIN, which is far less common than vulvar intraepithelial neoplasia (VIN) or cervical intraepithelial neoplasia (CIN), is an impediment to a thorough understanding of the disease process and its natural course. As a result, much of this information is an extrapolation of our knowledge of the pathophysiology of VIN and CIN.</p><p>Diagnosis and management of patients with VaIN are reviewed here. VIN and CIN are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3235.html" rel="external">"Vulvar squamous intraepithelial lesions (vulvar intraepithelial neoplasia)"</a> and  <a class="medical medical_review" href="/z/d/html/3215.html" rel="external">"Cervical intraepithelial neoplasia: Management"</a> and  <a class="medical medical_review" href="/z/d/html/89208.html" rel="external">"Cervical intraepithelial neoplasia: Choosing excision versus ablation, and prognosis and follow-up after treatment"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>VaIN is defined by the presence of squamous cell atypia without invasion. The disease is classified according to the depth of epithelial involvement: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>VaIN 1 and 2</strong> involve the lower one-third and two-thirds of the epithelium, respectively (<a class="graphic graphic_picture graphicRef68837" href="/z/d/graphic/68837.html" rel="external">picture 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VaIN 3</strong> involves more than two-thirds of the epithelium.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Carcinoma in situ, which encompasses the full thickness of the epithelium, is included under VaIN 3.</p><p></p><p>In 2012, as part of the Lower Anogenital Squamous Terminology (LAST) Standardization Project for human papillomavirus-associated lesions, the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology (ASCCP) proposed a revised terminology by which VaIN is reported using a two-tiered nomenclature: <strong>vaginal low-grade squamous intraepithelial lesion (LSIL)</strong> for low-grade disease (VaIN 1) and <strong>vaginal high-grade squamous intraepithelial lesion (HSIL)</strong> for high-grade disease (VaIN 3) [<a href="#rid1">1</a>]. VaIN 2 is an <strong>intermediate</strong> lesion that is usually reclassified as either VaIN 1 or VaIN 3 on pathology review.</p><p>While clinically we often refer to VaIN using the LAST terminology, this topic will utilize the VaIN 1, 2, and 3 terminology as most studies present their data in this format. </p><p class="headingAnchor" id="H3"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The true incidence of VaIN is unknown but is estimated at 0.2 to 0.3 cases per 100,000 females in the United States [<a href="#rid2">2</a>]. The average patient is between 43 and 60 years of age [<a href="#rid3">3-5</a>]. </p><p>The incidence of vaginal carcinoma in situ (a subset of VaIN 3, as discussed above) is estimated at 0.1 cases per 100,000 females in the United States and peaks between the ages of 70 to 79 years, slightly younger than the peak incidence age for vaginal carcinoma [<a href="#rid6">6</a>].</p><p>In patients who undergo hysterectomy for cervical intraepithelial neoplasia, the incidence of subsequently developing VaIN 2+ is as high as 7.4 percent [<a href="#rid7">7</a>]. (See <a class="local">'Classification'</a> above.)</p><p class="headingAnchor" id="H4"><span class="h1">RISK FACTORS, PATHOGENESIS, AND PREVENTION</span></p><p class="headingAnchor" id="H2905249455"><span class="h2">Human papillomavirus</span><span class="headingEndMark"> — </span>Human papillomavirus (HPV) is the most common cause of VaIN [<a href="#rid3">3</a>]. Most VaIN 3 lesions are associated with at least one high-risk HPV subtype (<a class="graphic graphic_table graphicRef57576" href="/z/d/graphic/57576.html" rel="external">table 1</a>), with HPV 16 and 18 being the most prevalent subtypes [<a href="#rid8">8-10</a>].</p><p>A review of 232 published VaIN cases reported the following prevalence of HPV: 99 percent in VaIN 1 and 93 percent in VaIN 2,3 [<a href="#rid11">11</a>]. A worldwide collaborative found a similarly high prevalence of HPV in VaIN 2,3 (96 percent) [<a href="#rid8">8</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>VaIN is consistently associated with prior or concurrent neoplasia elsewhere in the lower genital tract. Because HPV-associated lesions are often <strong>multifocal</strong> (originating within several discrete foci at one anatomic site) and <strong>multicentric</strong> (involving several distinct anatomic sites of the lower genital tract), up to 50 to 90 percent of patients with VaIN had or currently have either intraepithelial neoplasia or carcinoma of the cervix, vulva, anus, or perianal region [<a href="#rid4">4,12-16</a>].</p><p></p><p class="bulletIndent1">Patients who develop VaIN shortly after surgery for cervical intraepithelial neoplasia (CIN) may simply have vaginal extension of cervical disease that was not detected and treated. However, VaIN is frequently multifocal, can occur years after a hysterectomy for neoplasia, is independent of the amount of vaginal cuff excised, and is often observed de novo in the absence of cervical disease [<a href="#rid7">7,17-22</a>]. Approximately 1 to 7 percent of patients undergoing hysterectomy for CIN develop VaIN a few months to several years after surgery [<a href="#rid7">7,18-20,23</a>]. For example, one study found VaIN in 5 percent of 793 patients followed for 10 years after surgery for CIN 3 [<a href="#rid21">21</a>], and another study found the average time to diagnosis of VaIN after hysterectomy in patients with benign disease was 11 years, compared with 1 year among patients with CIN [<a href="#rid22">22</a>]. Thus, it is unlikely that VaIN is the result of extension from the cervix in every case.</p><p></p><p class="bulletIndent1">Similarly, patients treated for vulvar neoplasia are at high risk of developing VaIN. In one retrospective study including 302 patients who underwent surgery for vulvar intraepithelial neoplasia (VIN) or cancer and followed for 72 months (median), abnormal cervical/vaginal cytology was present in 25 percent of patients and VaIN 2+ developed in 9 percent of patients [<a href="#rid24">24</a>]. Risk factors on multivariate analysis included prior abnormal cytology (odds ratio [OR] 3.4, 95% CI 1.6-7.6) and immunodeficiency (OR 3.4, 95% CI 1.3-8.8). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The disparity between the relatively high incidence of CIN and rarity of VaIN in patients who test positive for HPV may be due to increased susceptibility of the metaplastic transformation zone of the cervix to oncogenic stimuli. By contrast, the mature, stable, squamous epithelium of the vagina may be less vulnerable to the same stimuli [<a href="#rid25">25</a>]. Patients who have been exposed to diethylstilbestrol (DES) in utero often have squamous metaplasia of the vagina; this observation may explain the increased incidence of VaIN noted in some studies of these patients [<a href="#rid26">26,27</a>]. However, these patients are also at risk for atypical vaginal adenosis and DES-associated clear cell adenocarcinoma, which are separate entities from VaIN and are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5427.html" rel="external">"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals", section on 'Females exposed to DES in utero (DES daughters)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prevalence of oncogenic HPV subtypes in the vagina is similar in patients who have and have not undergone hysterectomy [<a href="#rid28">28</a>]. Thus, presence of the cervix does not appear to be necessary for oncogenic HPV to infect the genital tract. In fact, subsequent occult vaginal invasion appears to be more common in patients with CIN treated with hysterectomy than in those whose cervix was retained [<a href="#rid22">22</a>]. This may be the result of lower rates of follow-up cytology and more difficult examination of the vaginal apex in hysterectomized patients. It may also be a result of selection bias since only patients with no cervical dysplasia are likely to have their cervix retained. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low levels of education, low family income, and history of vaginal condyloma have all been identified as risk factors for developing VaIN; however, all of these factors are also dependent variables predicting exposure to HPV [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HPV vaccination could potentially prevent approximately 70 percent of VaIN cases [<a href="#rid30">30,31</a>]. In one cohort study including over 500,000 female patients ages 17 to 26 years, HPV-vaccinated patients (82 percent) had lower rates of VaIN 3 or worse compared with HPV-unvaccinated patients (adjusted hazard ratio 0.30, 95% CI 0.13-0.68); the cumulative incidence of disease, however, was low [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a>.)</p><p></p><p class="headingAnchor" id="H3830539744"><span class="h2">Other risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunodeficiency</strong> – VaIN is more common in patients with genetic and acquired immunosuppression, including HIV infection [<a href="#rid33">33-35</a>]. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3228.html" rel="external">"Vulvar and vaginal intraepithelial neoplasia in patients with HIV infection"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cigarette smoking</strong> – Some data suggest an increased risk for VaIN 2,3 in high-risk HPV-positive patients who smoke compared with high-risk HPV-positive nonsmokers [<a href="#rid36">36</a>]. Smoking cessation is recommended to decrease the likelihood of VaIN.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The data regarding the role of <strong>previous radiation treatment</strong> in the development of secondary neoplasia of the vagina are conflicting [<a href="#rid37">37,38</a>].</p><p></p><p class="headingAnchor" id="H1302043365"><span class="h1">NATURAL HISTORY</span><span class="headingEndMark"> — </span>The natural course of VaIN has not been fully characterized. Although there have been no prospective studies, several retrospective investigations of various treatment modalities of VaIN have reported that 2 to 8 percent of cases of VaIN progress to invasive vaginal carcinoma [<a href="#rid12">12-14,39-43</a>]. </p><p>One study, as an example, found that 9 of 32 patients undergoing vaginectomy for VaIN 3 had foci of invasive carcinoma upon histologic examination [<a href="#rid39">39</a>]. In another study, among patients with VaIN 3 who underwent excisional therapy, 4 of 39 (10 percent) were found to have vaginal carcinoma [<a href="#rid44">44</a>]. In another series, 18 of 23 patients with VaIN followed expectantly for at least three years had complete regression of their lesions, three patients had persistent disease, and two (one with VaIN 3 and another with a lower grade lesion) progressed to invasive carcinoma resulting in an estimated lifetime risk of malignant transformation of VaIN to invasive vaginal carcinoma of 9 to 10 percent [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H3880413288"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>VaIN is usually asymptomatic, although patients can present with postcoital spotting or vaginal discharge. It should be excluded in all patients with an abnormal Pap smear who are posthysterectomy or who do not have identifiable cervical lesions that could account for the abnormality.</p><p class="headingAnchor" id="H7"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>The following components are part of the diagnostic evaluation for patients with suspected VaIN.</p><p class="headingAnchor" id="H2115404000"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>A gynecologic examination should be performed, with thorough inspection and palpation of the vagina for lesions, color changes, ulceration, and thickening or irregularity of the vaginal wall. The majority of VaIN lesions are located in the upper one-third of the vagina, and multiple lesions occur in over 50 percent of patients [<a href="#rid45">45,46</a>]. </p><p class="headingAnchor" id="H4256220242"><span class="h2">Colposcopy</span><span class="headingEndMark"> — </span>A thorough colposcopic assessment of the entire vagina should be performed for any patient with the above physical examination findings. </p><p>After the insertion of a speculum and the application of acetic acid, VaIN lesions will appear as raised or flat white, granular epithelium with sharply demarcated borders and may contain areas of vascular punctation. Lesions located in posthysterectomy vaginal recesses can be difficult to visualize; skin hooks may be used to gently evert these areas. The presence of a markedly irregular surface or severe vascular abnormalities with unusual branching suggests an invasive process, which warrants an excisional biopsy. Schiller or Lugol iodine solution can be used to detect lesions and confirm boundaries prior to excision.</p><p>In the postmenopausal patient, a few weeks of topical estrogen treatment will often accentuate visualization and improve detection of VaIN. </p><p class="headingAnchor" id="H8"><span class="h2">Biopsy technique</span><span class="headingEndMark"> — </span>The planned biopsy site is prepared with iodine or 4% <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">chlorhexidine</a>. Local anesthetic is injected (eg, 1 percent <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> without <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">epinephrine</a>). When a biopsy is attempted, it is helpful to partially close the speculum to allow the vagina to fold in on itself. Keeping the vagina taut makes performing a biopsy difficult. For sessile lesions, the biopsy is taken using a cervical biopsy forceps (eg, Kevorkian). Some raised or pedunculated lesions can be grasped with a forceps and biopsied using a fine scissor (eg, Metzenbaum). Hemostasis is usually obtained with application of Monsel solution or use of <a class="drug drug_general" data-topicid="9888" href="/z/d/drug information/9888.html" rel="external">silver nitrate</a>. If bleeding persists, a suture may be necessary.</p><p class="headingAnchor" id="H3759532198"><span class="h1">DIAGNOSIS AND DIFFERENTIAL</span></p><p class="headingAnchor" id="H591594050"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of VaIN is made by characteristic histologic findings on biopsy; specifically, VaIN is defined by the presence of squamous cell atypia without invasion. </p><p>In our practice, we review all VaIN pathology slides. As discussed above, VaIN 2 is considered to be an intermediate lesion (as classified by the Lower Anogenital Squamous Terminology [LAST] Standardization Project). During our review, we reclassify VaIN 2 into low-grade or high-grade lesions, which affects management considerably. (See <a class="local">'Classification'</a> above and <a class="local">'Treatment'</a> below.)</p><p class="headingAnchor" id="H2798021905"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis includes vaginal cancer, which is distinguished from VaIN by the presence of invasion. (See  <a class="medical medical_review" href="/z/d/html/3221.html" rel="external">"Vaginal cancer"</a>.)</p><p>Other benign etiologies, such as Gartner duct cysts, vaginal polyps, vaginal adenosis, or endometriosis, are in the differential for both VaIN and vaginal cancer. These are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3221.html" rel="external">"Vaginal cancer", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The treatment of VaIN depends on grade (<a class="graphic graphic_algorithm graphicRef128552" href="/z/d/graphic/128552.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1665435899"><span class="h2">Low-grade VaIN</span><span class="headingEndMark"> — </span>We manage patients with low-grade VaIN (ie, VaIN 1 and VaIN 2 lesions that are reclassified as VaIN 1 on pathology review) with close surveillance rather than treatment (<a class="graphic graphic_algorithm graphicRef128552" href="/z/d/graphic/128552.html" rel="external">algorithm 1</a>). These low-grade lesions are often the result of infection with nononcogenic subtypes of human papillomavirus (HPV) and will regress spontaneously [<a href="#rid11">11</a>]. In postmenopausal patients, these lesions can be associated with atrophic changes and may respond to topical estrogen [<a href="#rid47">47</a>]. This is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5443.html" rel="external">"Genitourinary syndrome of menopause (vulvovaginal atrophy): Treatment", section on 'Vaginal estrogen therapy'</a>.)</p><p class="headingAnchor" id="H3955578280"><span class="h2">High-grade VaIN</span><span class="headingEndMark"> — </span>High-grade VaIN (ie, VaIN 3 and VaIN 2 lesions that are reclassified as VaIN 3 on pathology review) has a higher risk of progression to squamous cell carcinoma of the vagina and is therefore treated (<a class="graphic graphic_algorithm graphicRef128552" href="/z/d/graphic/128552.html" rel="external">algorithm 1</a>) (see <a class="local">'Posttreatment surveillance'</a> below). A broad range of treatment options are available and include excision, ablation, topical therapy, and radiation therapy.</p><p class="headingAnchor" id="H3821831350"><span class="h3">First-line options</span></p><p class="headingAnchor" id="H2996593104"><span class="h4">How to choose</span><span class="headingEndMark"> — </span>The goals of treatment for VaIN 3 are to prevent disease progression while minimizing potential treatment sequelae. Previous treatment failures, the presence of multifocal disease, the patient's general health and comorbidities, as well as a desire to preserve sexual function are factors to consider in selecting a therapeutic course.</p><p>Our first-line approach to treatment of VaIN 3 is as follows (<a class="graphic graphic_algorithm graphicRef128552" href="/z/d/graphic/128552.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Excision is required for those patients with VaIN in whom:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A diagnostic specimen is needed for further evaluation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A lesion is worrisome for possible invasive disease (eg, raised, ulcerative, or with irregular borders), irrespective of results from colposcopy/biopsy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lesions that cannot be fully visualized or that involve the vaginal vault or lateral fornices.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients lacking any of the features listed above, our approach is as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with single lesions, we treat with excision, provided that complete removal with satisfactory cosmetic and functional results is expected.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>By contrast, we suggest ablative therapy rather than excision for patients with the following:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Multifocal disease.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Lesions in which excision would disrupt normal anatomy significantly and impair functional results.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Occasionally, topical therapy is used as first-line treatment in patients with early lesions and multifocal disease or those who are poor surgical candidates. (See <a class="local">'Subsequent-line options'</a> below.)</p><p></p><p>Complications most commonly associated with both excision and ablation include pain, scarring, and sexual dysfunction. In terms of efficacy, a review of 21 available studies on therapeutic modalities found that cure rates for VaIN were similar for excision, laser ablation, and an ultrasonic aspirator and dissector (69.0 to 87.5 percent) [<a href="#rid48">48</a>]. </p><p class="headingAnchor" id="H11"><span class="h4">Surgical therapy</span><span class="headingEndMark"> — </span>Surgical excision is the mainstay of VaIN treatment (<a class="graphic graphic_table graphicRef58294" href="/z/d/graphic/58294.html" rel="external">table 2</a>). (See <a class="local">'How to choose'</a> above.)</p><p>This approach permits histologic diagnosis, which is a significant advantage over other treatments since invasive foci have been detected in up to 10 to 28 percent of specimens [<a href="#rid22">22,44</a>]. Surgical approaches include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wide local excision</strong> is the most commonly performed surgical procedure for VaIN 3. It is usually performed transvaginally, although at times an open or minimally invasive abdominal approach is necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partial vaginectomy</strong> is required when VaIN is buried in posthysterectomy suture recesses since these lesions are frequently inaccessible to other forms of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Total vaginectomy</strong> is performed rarely and reserved for extensive and persistent disease.</p><p></p><p>These surgical excision procedures are discussed in detail elsewhere. (See <a class="local">'Subsequent-line options'</a> below and  <a class="medical medical_review" href="/z/d/html/3281.html" rel="external">"Vaginectomy"</a>.)</p><p>Complications of surgical therapy range from shortening or stenosis of the vagina due to wide local excisions to significant postoperative morbidity following abdominal procedures. The risk of complications is significantly increased in previously irradiated patients (for example, in patients with previously treated cervical cancer) [<a href="#rid4">4</a>]. Electrosurgical loop excision, laser vaginectomy, and ultrasonic surgical aspiration are modifications of the cold-knife approach that may promote rapid healing and reduce the frequency of complications [<a href="#rid49">49-52</a>].</p><p class="headingAnchor" id="H12"><span class="h4">Ablation</span><span class="headingEndMark"> — </span>Ablative therapy is only performed if the lesion is fully visualized and invasive disease has been excluded by biopsy. It is typically preferred for younger patients and in those patients with multifocal disease to preserve normal anatomy. (See <a class="local">'How to choose'</a> above.)</p><p>Two commonly used ablative techniques include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CO</strong><strong><sub>2</sub></strong><strong> laser</strong> – The procedure is generally well tolerated, heals satisfactorily, and results in minimal sexual dysfunction (<a class="graphic graphic_table graphicRef57738" href="/z/d/graphic/57738.html" rel="external">table 3</a>) [<a href="#rid53">53-61</a>]. Pain and bleeding are the most frequent complications, requiring intervention in 20 percent of patients in one series [<a href="#rid62">62</a>]. Approximately one-third of patients will require more than one treatment with CO<sub>2</sub> laser.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ultrasonic surgical aspiration</strong> is associated with less postoperative pain and less vulvar scarring compared with CO<sub>2</sub> laser [<a href="#rid51">51</a>].</p><p></p><p class="headingAnchor" id="H4188541812"><span class="h3">Subsequent-line options</span><span class="headingEndMark"> — </span>While surgery and ablation are the most common treatment methods for VaIN 3, a variety of alternate, less radical modalities have been used and studied. Topical therapy is a common next-line option for treatment of disease recurrence.</p><p>Topical application of therapeutic agents has the advantage of treating the entire vaginal mucosa, with good coverage of multifocal disease and disease in folds and recesses of the vagina. As with ablation, a prerequisite for topical treatment is that invasion has been excluded by thorough colposcopic examination and biopsy. Complications most commonly associated with topical therapies include pain, irritation, and superficial ulcerations. </p><p class="headingAnchor" id="H14"><span class="h4">Preferred: Imiquimod</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">Imiquimod</a> may be a reasonably effective and well-tolerated topical therapy option for the treatment of VaIN 3. One reported regimen is 5% imiquimod cream applied to the vaginal lesions three times a week for eight weeks [<a href="#rid63">63</a>]. The most common adverse events are local burning and soreness, which are generally not severe enough for patients to discontinue treatment. </p><p>In a systematic review and meta-analysis of six studies including 94 patients with any grade VaIN, 5% <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> was associated with a complete response (CR) rate of 77 percent (95% CI 59.4-98.5) and an HPV clearance rate of 53 percent (95% CI 29.5-93.6) [<a href="#rid64">64</a>]. In a subsequent systematic review including 37 patients with VaIN 2 or 3, treatment with imiquimod resulted in a 76 percent CR rate; response rates were higher in patients with prior hysterectomy compared with patients without hysterectomy [<a href="#rid65">65</a>]. Larger studies with standardized treatment protocols and longer follow-up are needed to make safe conclusions regarding the effectiveness, recurrence rates, and durability (recurrence-free interval) of this treatment.</p><p class="headingAnchor" id="H15"><span class="h4">Alternative: Fluorouracil</span><span class="headingEndMark"> — </span>Successful treatment of high-grade VaIN with <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) has been reported in the literature with failure rates comparable to other techniques (<a class="graphic graphic_table graphicRef56109" href="/z/d/graphic/56109.html" rel="external">table 4</a>) [<a href="#rid57">57,59,66-71</a>]. Several dosing protocols have been suggested, ranging from twice daily application for 14 days to once weekly for 10 weeks. Complications of topical FU include vaginal irritation or burning and ulcerations [<a href="#rid67">67,72</a>]. External <a class="drug drug_general" data-topicid="10326" href="/z/d/drug information/10326.html" rel="external">zinc oxide</a> cream or petroleum jelly can be used as a barrier to help protect against ulceration in adjacent areas. Topical estrogen may also reduce patient discomfort. </p><p>In a meta-analysis including 14 observational studies including 358 patients with VaIN and treated with a first course of 5% FU, the overall CR rate was 82 percent; patients with high-grade VaIN had a CR rate of 78 percent [<a href="#rid73">73</a>].</p><p>A study of insertion of 2 g topical 5% FU cream at night once every two weeks for eight doses for the treatment of cervical intraepithelial neoplasia in young patients reported at least one side effect in 48 percent of patients (epithelial disruption, discharge, pain, burning); however, in no participant were these side effects so severe that they would interfere with usual activities [<a href="#rid74">74</a>]. Columnar metaplasia of the vaginal mucosa can occur after topical FU; the clinical significance of this finding is not known [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Last-line option</span></p><p class="headingAnchor" id="H3757296683"><span class="h4">Radiation</span><span class="headingEndMark"> — </span>Intracavitary radiation therapy is reserved for patients who have failed previous treatments, are poor surgical candidates, or who have extensive, multifocal disease. While radiation is an effective form of treatment, it is rarely used because simple resection of the cuff or ablative therapy is usually successful, and radiation is associated with higher rates of morbidity than other therapies. Vaginal complications caused by intracavitary radiation include atrophy, stenosis, and shortening. These anatomic distortions can interfere with sexual function and are an impediment to thorough colposcopic follow-up. Bowel and bladder changes and the induction of menopause can also occur. Poor wound healing of irradiated tissue is a concern for patients who subsequently require surgical intervention [<a href="#rid20">20</a>].</p><p>In one study of 14 patients who received high dose rate brachytherapy for VaIN 3, disease regressed (12 of 14; 85 percent), progressed to invasive cancer (1 of 12; 7 percent), or persisted (1 of 12; 7 percent) during a median follow-up of 46 months [<a href="#rid76">76</a>]. A study demonstrated the effectiveness of high dose rate brachytherapy with an 88 percent success rate for the treatment of VaIN in 34 patients with minimal acute side effects and 44 percent with mostly mild late toxicities [<a href="#rid77">77</a>]. In another series with median follow-up of 77 months, regression occurred in 17 of 22 patients who received medium dose rate brachytherapy for VaIN 3 [<a href="#rid78">78</a>]. Low dose rate brachytherapy has also been used [<a href="#rid79">79</a>]. </p><p class="headingAnchor" id="H17"><span class="h1">POSTTREATMENT SURVEILLANCE</span><span class="headingEndMark"> — </span>Management of VaIN requires long-term follow-up given a significant risk of progression to cancer for these patients irrespective of treatment modality used [<a href="#rid80">80</a>]. </p><p>In a multicenter retrospective case study of 205 patients with biopsy-proven VaIN 2 or 3, progression to squamous cell carcinoma of the vagina was observed in nearly 6 percent of patients with a mean follow-up of 57 months (range 4 to 254 months) [<a href="#rid80">80</a>]. Patients at increased risk for progression were those with VaIN 3 (15 compared with 1.4 percent with VaIN 2) and those with prior hysterectomy for human papillomavirus (HPV)-related disease (17 versus 1.4 percent in nonhysterectomized patients). In a subsequent study including 337 patients with VaIN 3, rates of disease persistence, progression, and recurrence were 8.6, 7.4, and 4.2 percent, respectively, during the 14 month (median) follow-up period; older age and prior hysterectomy for cervical dysplasia were risk factors for progression [<a href="#rid81">81</a>]. Other studies have reported higher rates of disease recurrence, with one literature review reporting an 18 percent recurrence rate (range 0 to 50 percent) during follow-up periods of three months to 18 years (<a class="graphic graphic_table graphicRef58294" href="/z/d/graphic/58294.html" rel="external">table 2</a>) [<a href="#rid4">4,13,18,22,39,40,50</a>]. Recurrences of VaIN have also been described in vaginal tissue grafts performed to reconstruct the vagina after vaginectomy [<a href="#rid82">82</a>].</p><p>Posttreatment follow-up should include the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Clinical examination every six months for two years and annually thereafter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Annual co-testing (cytology and HPV).</p><p></p><p class="bulletIndent1">Given the high prevalence of HPV in VaIN, HPV testing, in addition to cytology, is preferred where available. In a retrospective study including 3229 patients with VaIN (over half of whom had VaIN 2 or 3), co-testing compared with cytology alone had higher sensitivity for VaIN only (97 versus 76 percent), concomitant VaIN (97 versus 79 percent), and VaIN after hysterectomy (98 versus 83 percent) [<a href="#rid83">83</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repeat colposcopy is performed for <strong>any</strong> HPV-positive test or any cytologic abnormality.</p><p></p><p class="headingAnchor" id="H2799713906"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113636.html" rel="external">"Society guideline links: Vulvar cancer and vaginal cancer"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Vaginal intraepithelial neoplasia (VaIN) is defined by the presence of squamous cell atypia without invasion. The disease is classified according to the depth of epithelial involvement: VaIN 1 involves the lower one-third of the epithelium and VaIN 3 involves more than two-thirds of the epithelium (<a class="graphic graphic_picture graphicRef68837" href="/z/d/graphic/68837.html" rel="external">picture 1</a>). VaIN 2 is an intermediate lesion and is often reclassified to low-grade (VaIN 1) or high-grade (VaIN 3) on pathology review. (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – VaIN is usually asymptomatic, although patients can present with postcoital spotting or vaginal discharge. It should be excluded in all patients with an abnormal Pap smear who are posthysterectomy or who do not have identifiable cervical lesions that could account for the abnormality. (See <a class="local">'Clinical presentation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – Evaluation includes a thorough gynecologic examination with colposcopy and biopsies of any concerning lesions. Diagnosis is made by characteristic histologic findings on biopsy. In our practice, we review all VaIN pathology slides and reclassify VaIN 2 into VaIN 1 (low-grade) or VaIN 3 (high-grade) lesions. (See <a class="local">'Diagnostic evaluation'</a> above and <a class="local">'Diagnosis and differential'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Treatment of VaIN depends on whether it is a low-grade or high-grade lesion (<a class="graphic graphic_algorithm graphicRef128552" href="/z/d/graphic/128552.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low-grade VaIN</strong> – For patients with low-grade disease (VaIN 1 and VaIN 2 lesions that are reclassified as VaIN 1 on pathology review),<strong> </strong>we suggest surveillance rather than surgical treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). These lesions are often the result of infection with nononcogenic subtypes of human papillomavirus (HPV) or atrophic changes and will often regress spontaneously. (See <a class="local">'Low-grade VaIN'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>High-grade</strong> <strong>VaIN </strong>– For patients with high-grade lesions (VaIN 3 and VaIN 2 lesions that are reclassified as VaIN 3 on pathology review), we suggest excision or ablation rather than surveillance (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The goals of treatment are to prevent disease progression while minimizing potential treatment sequelae. (See <a class="local">'High-grade VaIN'</a> above and <a class="local">'How to choose'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with a single lesion or lesions that are worrisome for possible invasive disease (eg, raised, ulcerative, or with irregular borders), we suggest surgical excision rather than ablation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Excision is also favored for lesions that cannot be fully visualized (eg, lesions involving the vaginal vault or lateral fornices). (See <a class="local">'Surgical therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with multifocal disease that is completely visualized, we suggest ablation rather than surgical excision (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, invasive disease must first be excluded by biopsy prior to proceeding with ablation. (See <a class="local">'Ablation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Recurrent VaIN</strong> – For patients with recurrent disease, we suggest topical therapy with <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">imiquimod</a> rather than a repeat excision or ablation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Topical <a class="drug drug_general" data-topicid="8464" href="/z/d/drug information/8464.html" rel="external">fluorouracil</a> is a less commonly used alternative. These medications have the advantage of treating the entire vaginal mucosa, with good coverage of multifocal disease and disease in folds and recesses of the vagina. As with ablation, invasive disease must be excluded prior to treatment with topical therapies. (See <a class="local">'Subsequent-line options'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Last-line therapy</strong> – A last-line option<strong> </strong>for the treatment of VaIN 3 is radiation therapy. We suggest radiation for patients who have failed previous treatments, are poor surgical candidates, or who have extensive, multifocal disease. Radiation is associated with higher rates of morbidity than other therapies. (See <a class="local">'Last-line option'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posttreatment surveillance</strong> – Management of VaIN requires long-term follow-up. In our practice, we perform HPV-based testing and clinical examination every six months for two years and annually thereafter to evaluate for persistent or progressive disease. (See <a class="local">'Posttreatment surveillance'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012; 136:1266.</a></li><li><a class="nounderline abstract_t">Henson D, Tarone R. An epidemiologic study of cancer of the cervix, vagina, and vulva based on the Third National Cancer Survey in the United States. Am J Obstet Gynecol 1977; 129:525.</a></li><li><a class="nounderline abstract_t">Sugase M, Matsukura T. Distinct manifestations of human papillomaviruses in the vagina. Int J Cancer 1997; 72:412.</a></li><li><a class="nounderline abstract_t">Cheng D, Ng TY, Ngan HY, Wong LC. Wide local excision (WLE) for vaginal intraepithelial neoplasia (VAIN). Acta Obstet Gynecol Scand 1999; 78:648.</a></li><li><a class="nounderline abstract_t">Herbst AL, Green TH Jr, Ulfelder H. Primary carcinoma of the vagina. An analysis of 68 cases. Am J Obstet Gynecol 1970; 106:210.</a></li><li><a class="nounderline abstract_t">Watson M, Saraiya M, Wu X. Update of HPV-associated female genital cancers in the United States, 1999-2004. J Womens Health (Larchmt) 2009; 18:1731.</a></li><li><a class="nounderline abstract_t">Schockaert S, Poppe W, Arbyn M, et al. Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study. Am J Obstet Gynecol 2008; 199:113.e1.</a></li><li><a class="nounderline abstract_t">Alemany L, Saunier M, Tinoco L, et al. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer 2014; 50:2846.</a></li><li><a class="nounderline abstract_t">Insinga RP, Liaw KL, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008; 17:1611.</a></li><li><a class="nounderline abstract_t">Garland SM, Joura EA, Ault KA, et al. Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age. Obstet Gynecol 2018; 132:261.</a></li><li><a class="nounderline abstract_t">Smith JS, Backes DM, Hoots BE, et al. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol 2009; 113:917.</a></li><li><a class="nounderline abstract_t">Aho M, Vesterinen E, Meyer B, et al. Natural history of vaginal intraepithelial neoplasia. Cancer 1991; 68:195.</a></li><li><a class="nounderline abstract_t">Sillman FH, Fruchter RG, Chen YS, et al. Vaginal intraepithelial neoplasia: risk factors for persistence, recurrence, and invasion and its management. Am J Obstet Gynecol 1997; 176:93.</a></li><li><a class="nounderline abstract_t">Gunderson CC, Nugent EK, Elfrink SH, et al. A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia. Am J Obstet Gynecol 2013; 208:410.e1.</a></li><li><a class="nounderline abstract_t">Sturgeon SR, Curtis RE, Johnson K, et al. Second primary cancers after vulvar and vaginal cancers. Am J Obstet Gynecol 1996; 174:929.</a></li><li><a class="nounderline abstract_t">Albuquerque A, Godfrey MAL, Cappello C, et al. Multizonal anogenital neoplasia in women: a cohort analysis. BMC Cancer 2021; 21:232.</a></li><li><a class="nounderline abstract_t">Creasman WT, Rutledge F. Carcinoma in situ of the cervix. An analysis of 861 patients. Obstet Gynecol 1972; 39:373.</a></li><li><a class="nounderline abstract_t">Lenehan PM, Meffe F, Lickrish GM. Vaginal intraepithelial neoplasia: biologic aspects and management. Obstet Gynecol 1986; 68:333.</a></li><li><a class="nounderline abstract_t">Nwabineli NJ, Monaghan JM. Vaginal epithelial abnormalities in patients with CIN: clinical and pathological features and management. Br J Obstet Gynaecol 1991; 98:25.</a></li><li><a class="nounderline abstract_t">Ogino I, Kitamura T, Okajima H, Matsubara S. High-dose-rate intracavitary brachytherapy in the management of cervical and vaginal intraepithelial neoplasia. Int J Radiat Oncol Biol Phys 1998; 40:881.</a></li><li><a class="nounderline abstract_t">Kalogirou D, Antoniou G, Karakitsos P, et al. Vaginal intraepithelial neoplasia (VAIN) following hysterectomy in patients treated for carcinoma in situ of the cervix. Eur J Gynaecol Oncol 1997; 18:188.</a></li><li><a class="nounderline abstract_t">Ireland D, Monaghan JM. The management of the patient with abnormal vaginal cytology following hysterectomy. Br J Obstet Gynaecol 1988; 95:973.</a></li><li><a class="nounderline abstract_t">Kim JH, Kim J, Kim K, et al. Risk Factor and Treatment of Vaginal Intraepithelial Neoplasia After Hysterectomy for Cervical Intraepithelial Neoplasia. J Low Genit Tract Dis 2022; 26:147.</a></li><li><a class="nounderline abstract_t">Buchanan TR, Zamorano AS, Massad LS, et al. Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6 year follow-up study. Gynecol Oncol 2019; 155:88.</a></li><li><a class="nounderline abstract_t">Schneider A, de Villiers EM, Schneider V. Multifocal squamous neoplasia of the female genital tract: significance of human papillomavirus infection of the vagina after hysterectomy. Obstet Gynecol 1987; 70:294.</a></li><li><a class="nounderline abstract_t">Bornstein J, Adam E, Adler-Storthz K, Kaufman RH. Development of cervical and vaginal squamous cell neoplasia as a late consequence of in utero exposure to diethylstilbestrol. Obstet Gynecol Surv 1988; 43:15.</a></li><li class="breakAll">Townsend DE. Intraepithelial neoplasia of the vagina. In: Gynecologic oncology: Fundamental principles and clinical practice, Coppleson M (Ed), Churchill Livingstone, Edinburgh 1992. p.493.</li><li><a class="nounderline abstract_t">Castle PE, Schiffman M, Bratti MC, et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. J Infect Dis 2004; 190:458.</a></li><li><a class="nounderline abstract_t">Brinton LA, Nasca PC, Mallin K, et al. Case-control study of in situ and invasive carcinoma of the vagina. Gynecol Oncol 1990; 38:49.</a></li><li><a class="nounderline abstract_t">FUTURE I/II Study Group, Dillner J, Kjaer SK, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010; 341:c3493.</a></li><li><a class="nounderline abstract_t">Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007; 369:1693.</a></li><li><a class="nounderline abstract_t">Dehlendorff C, Baandrup L, Kjaer SK. Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers. J Natl Cancer Inst 2021; 113:869.</a></li><li><a class="nounderline abstract_t">Sillman F, Stanek A, Sedlis A, et al. The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. Am J Obstet Gynecol 1984; 150:300.</a></li><li><a class="nounderline abstract_t">Spitzer M. Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management. Obstet Gynecol Surv 1999; 54:131.</a></li><li><a class="nounderline abstract_t">Conley LJ, Ellerbrock TV, Bush TJ, et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359:108.</a></li><li><a class="nounderline abstract_t">Sherman JF, Mount SL, Evans MF, et al. Smoking increases the risk of high-grade vaginal intraepithelial neoplasia in women with oncogenic human papillomavirus. Gynecol Oncol 2008; 110:396.</a></li><li><a class="nounderline abstract_t">Boice JD Jr, Engholm G, Kleinerman RA, et al. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 1988; 116:3.</a></li><li><a class="nounderline abstract_t">Lee JY, Perez CA, Ettinger N, Fineberg BB. The risk of second primaries subsequent to irradiation for cervix cancer. Int J Radiat Oncol Biol Phys 1982; 8:207.</a></li><li><a class="nounderline abstract_t">Hoffman MS, DeCesare SL, Roberts WS, et al. Upper vaginectomy for in situ and occult, superficially invasive carcinoma of the vagina. Am J Obstet Gynecol 1992; 166:30.</a></li><li><a class="nounderline abstract_t">Benedet JL, Sanders BH. Carcinoma in situ of the vagina. Am J Obstet Gynecol 1984; 148:695.</a></li><li><a class="nounderline abstract_t">Wharton JT, Tortolero-Luna G, Linares AC, et al. Vaginal intraepithelial neoplasia and vaginal cancer. Obstet Gynecol Clin North Am 1996; 23:325.</a></li><li><a class="nounderline abstract_t">Dodge JA, Eltabbakh GH, Mount SL, et al. Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia. Gynecol Oncol 2001; 83:363.</a></li><li><a class="nounderline abstract_t">Jentschke M, Hoffmeister V, Soergel P, Hillemanns P. Clinical presentation, treatment and outcome of vaginal intraepithelial neoplasia. Arch Gynecol Obstet 2016; 293:415.</a></li><li><a class="nounderline abstract_t">Sopracordevole F, De Piero G, Clemente N, et al. Vaginal Intraepithelial Neoplasia: Histopathological Upgrading of Lesions and Evidence of Occult Vaginal Cancer. J Low Genit Tract Dis 2016; 20:70.</a></li><li><a class="nounderline abstract_t">Boonlikit S, Noinual N. Vaginal intraepithelial neoplasia: a retrospective analysis of clinical features and colpohistology. J Obstet Gynaecol Res 2010; 36:94.</a></li><li><a class="nounderline abstract_t">Kim MK, Lee IH, Lee KH. Clinical outcomes and risk of recurrence among patients with vaginal intraepithelial neoplasia: a comprehensive analysis of 576 cases. J Gynecol Oncol 2018; 29:e6.</a></li><li><a class="nounderline abstract_t">Rhodes HE, Chenevert L, Munsell M. Vaginal intraepithelial neoplasia (VaIN 2/3): comparing clinical outcomes of treatment with intravaginal estrogen. J Low Genit Tract Dis 2014; 18:115.</a></li><li><a class="nounderline abstract_t">Gurumurthy M, Cruickshank ME. Management of vaginal intraepithelial neoplasia. J Low Genit Tract Dis 2012; 16:306.</a></li><li><a class="nounderline abstract_t">Patsner B. Treatment of vaginal dysplasia with loop excision: report of five cases. Am J Obstet Gynecol 1993; 169:179.</a></li><li><a class="nounderline abstract_t">Julian TM, O'Connell BJ, Gosewehr JA. Indications, techniques, and advantages of partial laser vaginectomy. Obstet Gynecol 1992; 80:140.</a></li><li><a class="nounderline abstract_t">von Gruenigen VE, Gibbons HE, Gibbins K, et al. Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial. Obstet Gynecol 2007; 109:942.</a></li><li><a class="nounderline abstract_t">Robinson JB, Sun CC, Bodurka-Bevers D, et al. Cavitational ultrasonic surgical aspiration for the treatment of vaginal intraepithelial neoplasia. Gynecol Oncol 2000; 78:235.</a></li><li><a class="nounderline abstract_t">Woodman CB, Jordan JA, Wade-Evans T. The management of vaginal intraepithelial neoplasia after hysterectomy. Br J Obstet Gynaecol 1984; 91:707.</a></li><li><a class="nounderline abstract_t">Townsend DE, Levine RU, Crum CP, Richart RM. Treatment of vaginal carcinoma in situ with the carbon dioxide laser. Am J Obstet Gynecol 1982; 143:565.</a></li><li><a class="nounderline abstract_t">Diakomanolis E, Rodolakis A, Sakellaropoulos G, et al. Conservative management of vaginal intraepithelial neoplasia (VAIN) by laser CO2. Eur J Gynaecol Oncol 1996; 17:389.</a></li><li><a class="nounderline abstract_t">Campagnutta E, Parin A, De Piero G, et al. Treatment of vaginal intraepithelial neoplasia (VAIN) with the carbon dioxide laser. Clin Exp Obstet Gynecol 1999; 26:127.</a></li><li><a class="nounderline abstract_t">Krebs HB. Treatment of vaginal intraepithelial neoplasia with laser and topical 5-fluorouracil. Obstet Gynecol 1989; 73:657.</a></li><li><a class="nounderline abstract_t">Stuart GC, Flagler EA, Nation JG, et al. Laser vaporization of vaginal intraepithelial neoplasia. Am J Obstet Gynecol 1988; 158:240.</a></li><li><a class="nounderline abstract_t">Audet-Lapointe P, Body G, Vauclair R, et al. Vaginal intraepithelial neoplasia. Gynecol Oncol 1990; 36:232.</a></li><li><a class="nounderline abstract_t">Hoffman MS, Roberts WS, LaPolla JP, et al. Laser vaporization of grade 3 vaginal intraepithelial neoplasia. Am J Obstet Gynecol 1991; 165:1342.</a></li><li><a class="nounderline abstract_t">Piovano E, Macchi C, Attamante L, et al. CO2 laser vaporization for the treatment of vaginal intraepithelial neoplasia: effectiveness and predictive factors for recurrence. Eur J Gynaecol Oncol 2015; 36:383.</a></li><li><a class="nounderline abstract_t">Sherman AI. Laser therapy for vaginal intraepithelial neoplasia after hysterectomy. J Reprod Med 1990; 35:941.</a></li><li><a class="nounderline abstract_t">Haidopoulos D, Diakomanolis E, Rodolakis A, et al. Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina? Int J Gynecol Cancer 2005; 15:898.</a></li><li><a class="nounderline abstract_t">Tranoulis A, Laios A, Mitsopoulos V, et al. Efficacy of 5% imiquimod for the treatment of Vaginal intraepithelial neoplasia-A systematic review of the literature and a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2017; 218:129.</a></li><li><a class="nounderline abstract_t">Inayama Y, Yamanishi Y, Nakatani E, et al. Imiquimod for vaginal intraepithelial neoplasia 2-3: A systematic review and meta-analysis. Gynecol Oncol 2021; 160:140.</a></li><li><a class="nounderline abstract_t">Petrilli ES, Townsend DE, Morrow CP, Nakao CY. Vaginal intraepithelial neoplasia: Biologic aspects and treatment with topical 5-fluorouracil and the carbon dioxide laser. Am J Obstet Gynecol 1980; 138:321.</a></li><li><a class="nounderline abstract_t">Caglar H, Hertzog RW, Hreshchyshyn MM. Topical 5-fluorouracil treatment of vaginal intraepithelial neoplasia. Obstet Gynecol 1981; 58:580.</a></li><li><a class="nounderline abstract_t">Daly JW, Ellis GF. Treatment of vaginal dysplasia and carcinoma in situ with topical 5-fluorouracil. Obstet Gynecol 1980; 55:350.</a></li><li><a class="nounderline abstract_t">Kirwan P, Naftalin NJ. Topical 5-fluorouracil in the treatment of vaginal intraepithelial neoplasia. Br J Obstet Gynaecol 1985; 92:287.</a></li><li><a class="nounderline abstract_t">Stefanon B, Pallucca A, Merola M, Bandieramonte G. Treatment with 5-fluorouracil of 35 patients with clinical or subclinical HPV infection of the vagina. Eur J Gynaecol Oncol 1996; 17:534.</a></li><li><a class="nounderline abstract_t">Fiascone S, Vitonis AF, Feldman S. Topical 5-Fluorouracil for Women With High-Grade Vaginal Intraepithelial Neoplasia. Obstet Gynecol 2017; 130:1237.</a></li><li><a class="nounderline abstract_t">Woodruff JD, Parmley TH, Julian CG. Topical 5-fluorouracil in the treatment of vaginal carcinoma-in-situ. Gynecol Oncol 1975; 3:124.</a></li><li><a class="nounderline abstract_t">Tranoulis A, Georgiou D, Laios A, et al. 5-Flouorouracil Is an Attractive Medical Treatment in Women With Vaginal Intraepithelial Neoplasia: A Meta-Analysis. J Low Genit Tract Dis 2018; 22:375.</a></li><li><a class="nounderline abstract_t">Rahangdale L, Lippmann QK, Garcia K, et al. Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial. Am J Obstet Gynecol 2014; 210:314.e1.</a></li><li><a class="nounderline abstract_t">Dungar CF, Wilkinson EJ. Vaginal columnar cell metaplasia. An acquired adenosis associated with topical 5-fluorouracil therapy. J Reprod Med 1995; 40:361.</a></li><li><a class="nounderline abstract_t">MacLeod C, Fowler A, Dalrymple C, et al. High-dose-rate brachytherapy in the management of high-grade intraepithelial neoplasia of the vagina. Gynecol Oncol 1997; 65:74.</a></li><li><a class="nounderline abstract_t">Song JH, Lee JH, Lee JH, et al. High-dose-rate brachytherapy for the treatment of vaginal intraepithelial neoplasia. Cancer Res Treat 2014; 46:74.</a></li><li><a class="nounderline abstract_t">Graham K, Wright K, Cadwallader B, et al. 20-year retrospective review of medium dose rate intracavitary brachytherapy in VAIN3. Gynecol Oncol 2007; 106:105.</a></li><li><a class="nounderline abstract_t">Blanchard P, Monnier L, Dumas I, et al. Low-dose-rate definitive brachytherapy for high-grade vaginal intraepithelial neoplasia. Oncologist 2011; 16:182.</a></li><li><a class="nounderline abstract_t">Sopracordevole F, Barbero M, Clemente N, et al. High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). Eur Rev Med Pharmacol Sci 2016; 20:818.</a></li><li><a class="nounderline abstract_t">Ao M, Zheng D, Wang J, et al. Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia. Gynecol Oncol 2021; 162:584.</a></li><li><a class="nounderline abstract_t">Lathrop JC, Ree HJ, McDuff HC Jr. Intraepithelial neoplasia of the neovagina. Obstet Gynecol 1985; 65:91S.</a></li><li><a class="nounderline abstract_t">Ao M, Zheng D, Wang J, et al. A retrospective study of cytology and HPV genotypes results of 3229 vaginal intraepithelial neoplasia patients. J Med Virol 2022; 94:737.</a></li></ol></div><div id="topicVersionRevision">Topic 3233 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22742517" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/199064" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An epidemiologic study of cancer of the cervix, vagina, and vulva based on the Third National Cancer Survey in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9247283" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Distinct manifestations of human papillomaviruses in the vagina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10422914" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Wide local excision (WLE) for vaginal intraepithelial neoplasia (VAIN).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5410047" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Primary carcinoma of the vagina. An analysis of 68 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19951205" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Update of HPV-associated female genital cancers in the United States, 1999-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456229" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence of vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25155250" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18628412" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29995724" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19305339" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2049744" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Natural history of vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024096" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vaginal intraepithelial neoplasia: risk factors for persistence, recurrence, and invasion and its management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23380265" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633671" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Second primary cancers after vulvar and vaginal cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33676451" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Multizonal anogenital neoplasia in women: a cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5019309" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Carcinoma in situ of the cervix. An analysis of 861 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3737055" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Vaginal intraepithelial neoplasia: biologic aspects and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1998628" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Vaginal epithelial abnormalities in patients with CIN: clinical and pathological features and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9531374" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : High-dose-rate intracavitary brachytherapy in the management of cervical and vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9174833" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Vaginal intraepithelial neoplasia (VAIN) following hysterectomy in patients treated for carcinoma in situ of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3191050" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The management of the patient with abnormal vaginal cytology following hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35238809" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk Factor and Treatment of Vaginal Intraepithelial Neoplasia After Hysterectomy for Cervical Intraepithelial Neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31375270" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6 year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2819794" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Multifocal squamous neoplasia of the female genital tract: significance of human papillomavirus infection of the vagina after hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2829071" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Development of cervical and vaginal squamous cell neoplasia as a late consequence of in utero exposure to diethylstilbestrol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2829071" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Development of cervical and vaginal squamous cell neoplasia as a late consequence of in utero exposure to diethylstilbestrol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15243917" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A population-based study of vaginal human papillomavirus infection in hysterectomized women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2354827" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Case-control study of in situ and invasive carcinoma of the vagina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647284" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17512854" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33377930" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6091459" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9950005" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Lower genital tract intraepithelial neoplasia in HIV-infected women: guidelines for evaluation and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11809252" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18586314" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Smoking increases the risk of high-grade vaginal intraepithelial neoplasia in women with oncogenic human papillomavirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3186929" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Radiation dose and second cancer risk in patients treated for cancer of the cervix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7085376" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The risk of second primaries subsequent to irradiation for cervix cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1733213" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Upper vaginectomy for in situ and occult, superficially invasive carcinoma of the vagina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6702936" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Carcinoma in situ of the vagina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8784884" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Vaginal intraepithelial neoplasia and vaginal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11606098" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical features and risk of recurrence among patients with vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26232937" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical presentation, treatment and outcome of vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26461231" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Vaginal Intraepithelial Neoplasia: Histopathological Upgrading of Lesions and Evidence of Occult Vaginal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20178533" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Vaginal intraepithelial neoplasia: a retrospective analysis of clinical features and colpohistology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29185264" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clinical outcomes and risk of recurrence among patients with vaginal intraepithelial neoplasia: a comprehensive analysis of 576 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24189311" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Vaginal intraepithelial neoplasia (VaIN 2/3): comparing clinical outcomes of treatment with intravaginal estrogen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22460272" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Management of vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8129807" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Treatment of vaginal dysplasia with loop excision: report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1603485" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Indications, techniques, and advantages of partial laser vaginectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17400858" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Surgical treatments for vulvar and vaginal dysplasia: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926809" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cavitational ultrasonic surgical aspiration for the treatment of vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6743614" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The management of vaginal intraepithelial neoplasia after hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6807094" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Treatment of vaginal carcinoma in situ with the carbon dioxide laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8933838" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Conservative management of vaginal intraepithelial neoplasia (VAIN) by laser CO2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459459" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Treatment of vaginal intraepithelial neoplasia (VAIN) with the carbon dioxide laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2927862" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Treatment of vaginal intraepithelial neoplasia with laser and topical 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2829628" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Laser vaporization of vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2404839" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1957858" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Laser vaporization of grade 3 vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26390687" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : CO2 laser vaporization for the treatment of vaginal intraepithelial neoplasia: effectiveness and predictive factors for recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2246761" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Laser therapy for vaginal intraepithelial neoplasia after hysterectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174242" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Can local application of imiquimod cream be an alternative mode of therapy for patients with high-grade intraepithelial lesions of the vagina?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28985547" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy of 5% imiquimod for the treatment of Vaginal intraepithelial neoplasia-A systematic review of the literature and a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33010966" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Imiquimod for vaginal intraepithelial neoplasia 2-3: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6774615" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Vaginal intraepithelial neoplasia: Biologic aspects and treatment with topical 5-fluorouracil and the carbon dioxide laser.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7301233" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Topical 5-fluorouracil treatment of vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7360434" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Treatment of vaginal dysplasia and carcinoma in situ with topical 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3978059" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Topical 5-fluorouracil in the treatment of vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8971537" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Treatment with 5-fluorouracil of 35 patients with clinical or subclinical HPV infection of the vagina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29112645" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Topical 5-Fluorouracil for Women With High-Grade Vaginal Intraepithelial Neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1183865" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Topical 5-fluorouracil in the treatment of vaginal carcinoma-in-situ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30132763" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : 5-Flouorouracil Is an Attractive Medical Treatment in Women With Vaginal Intraepithelial Neoplasia: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24384495" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7608876" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Vaginal columnar cell metaplasia. An acquired adenosis associated with topical 5-fluorouracil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9103394" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : High-dose-rate brachytherapy in the management of high-grade intraepithelial neoplasia of the vagina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24520226" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : High-dose-rate brachytherapy for the treatment of vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17481703" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : 20-year retrospective review of medium dose rate intracavitary brachytherapy in VAIN3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21262875" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Low-dose-rate definitive brachytherapy for high-grade vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27010135" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34226020" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risk factors analysis of persistence, progression and recurrence in vaginal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3883276" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Intraepithelial neoplasia of the neovagina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34460120" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : A retrospective study of cytology and HPV genotypes results of 3229 vaginal intraepithelial neoplasia patients.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
